Arcutis insider plans sale of 19,833 shares

Arcutis Biotherapeutics insider activity: A holder has filed to sell 19,833 shares of Arcutis Biotherapeutics common stock under Rule 144 through Merrill on the NASDAQ, with an approximate sale date of 02/02/2026.

Rhea-AI Filing Summary

Arcutis Biotherapeutics insider activity: A holder has filed to sell 19,833 shares of Arcutis Biotherapeutics common stock under Rule 144 through Merrill on the NASDAQ, with an approximate sale date of 02/02/2026. The filing notes 122,492,192 common shares outstanding for this class.

The 19,833 shares were acquired on 02/01/2026 via a restricted stock vest from Arcutis Biotherapeutics, Inc., with payment also dated 02/01/2026. In the prior three months, Todd F. Watanabe reported sales of 48,945 and 1,055 common shares, with gross proceeds of 1,485,759 and 31,650, respectively.

FAQ

What does the Arcutis (ARQT) Form 144 filing disclose?

The Form 144 discloses an intended sale of 19,833 Arcutis Biotherapeutics common shares under Rule 144. The shares are to be sold through Merrill on the NASDAQ, providing notice of a planned insider-related transaction in the company’s stock.

How many ARQT shares are planned for sale and on what date?

The filing states that 19,833 Arcutis Biotherapeutics common shares are planned for sale. The approximate sale date listed is 02/02/2026, giving the market advance notice of the timing and size of this intended Rule 144 transaction.

How were the Arcutis (ARQT) shares in this Form 144 acquired?

The 19,833 Arcutis shares were acquired on 02/01/2026 through a restricted stock vest from Arcutis Biotherapeutics, Inc. The amount of securities acquired matches the planned sale amount, and the payment date for the vesting is also listed as 02/01/2026.

Which broker and exchange are involved in the planned ARQT share sale?

The Form 144 lists Merrill, located at 8890 Lyra Dr, 5th Floor, Columbus, OH 43240, as the broker. The common shares are expected to be sold on the NASDAQ, indicating where trading for this planned Rule 144 sale is intended to occur.

What recent Arcutis (ARQT) share sales has Todd F. Watanabe reported?

Over the past three months, Todd F. Watanabe reported two sales of Arcutis common stock: 48,945 shares on 11/24/2025 for gross proceeds of 1,485,759, and 1,055 shares on 11/21/2025 for gross proceeds of 31,650, as detailed in the filing.

How many Arcutis (ARQT) common shares are outstanding in this filing?

The Form 144 states that there are 122,492,192 Arcutis Biotherapeutics common shares outstanding. This figure provides context for the planned sale of 19,833 shares, showing the relative size of the transaction compared with the total outstanding share count.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 05:41 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801061
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARCUTIS BIOTHERAPEUTICS, INC.
SEC File Number	001-39186
Address of Issuer	3027 Townsgate Road Suite 300 Westlake Village, CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Todd Frank Watanabe
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr 5th Flr Columbus OH 43240	19833	505710	122492192	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Restricted stock vest	Arcutis Biotherapeutics, Inc			19833	02/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Todd F Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	11/24/2025	48945	1485759
Todd F Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	11/21/2025	1055	31650

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Todd Frank Watanabe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)